ArticleCureus2025
Non-Asbestos-Related Malignant Peritoneal Mesothelioma: A Diagnostic Challenge in a Case of Unexplained Ascites.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Malignant peritoneal mesothelioma (MPM) is a rare and aggressive malignancy arising from mesothelial cells of the peritoneum. It is most frequently linked to asbestos exposure, although up to half of cases occur without such history. Because of its vague and non-specific presentation, diagnosis is often delayed; cytology is frequently non-diagnostic, and histological confirmation with immunohistochemistry is required. Prognosis remains poor, although advances in cytoreductive surgery and intraperitoneal chemotherapy have improved outcomes in selected patients. We describe a man in his late 60s with no history of asbestos exposure who presented with progressive abdominal distension over 18 months. He underwent repeated paracenteses with negative cytology and multiple imaging studies, initially attributed to an intraductal papillary mucinous neoplasm (IPMN) under surveillance. Subsequent computed tomography (CT) demonstrated extensive peritoneal disease with omental caking and splenic lesions. Omental biopsy confirmed epithelioid-type MPM with BRCA1-associated protein 1 (BAP1) loss on immunohistochemistry. Given advanced disease and poor performance status, the patient was deemed unsuitable for surgery or chemotherapy and was managed with best supportive palliative care. This case highlights the diagnostic challenges of MPM, particularly in the absence of asbestos exposure and in the presence of coexistent pathology, and underscores the importance of early histological evaluation in patients with unexplained recurrent ascites.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.